DCM
PCRX icon

Daruma Capital Management’s Pacira BioSciences PCRX Stock Holding History

Daruma Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-177,242
Closed -$6.75M – 22
2019
Q1 		$6.75M Sell
177,242
-282,319
-61% -$11M 0.77% 32
2018
Q4 		$19.8M Sell
459,561
-48,079
-9% -$2.24M 2.63% 20
2018
Q3 		$25M Sell
507,640
-673,610
-57% -$29.1M 2.35% 26
2018
Q2 		$37.9M Buy
1,181,250
+44,030
+4% +$1.52M 2.46% 25
2018
Q1 		$35.4M Sell
1,137,220
-93,634
-8% -$3.33M 2.21% 28
2017
Q4 		$56.2M Buy
1,230,854
+8,199
+0.7% +$325K 3.5% 12
2017
Q3 		$45.9M Buy
1,222,655
+100,730
+9% +$4.05M 2.86% 22
2017
Q2 		$53.5M Sell
1,121,925
-36,774
-3% -$1.71M 3.19% 11
2017
Q1 		$52.8M Sell
1,158,699
-60,943
-5% -$2.63M 3.08% 15
2016
Q4 		$39.4M Sell
1,219,642
-402
-0% -$13.4K 2.24% 28
2016
Q3 		$41.8M Buy
1,220,044
+143,320
+13% +$5.62M 2.55% 25
2016
Q2 		$36.3M Buy
1,076,724
+113,540
+12% +$5.58M 2.37% 27
2016
Q1 		$51M Buy
963,184
+14,901
+2% +$872K 3.19% 18
2015
Q4 		$72.8M Sell
948,283
-93,729
-9% -$5.31M 4.36% 1
2015
Q3 		$42.8M Buy
1,042,012
+374,135
+56% +$22.9M 2.63% 26
2015
Q2 		$47.2M Buy
667,877
+7,879
+1% +$621K 2.07% 29
2015
Q1 		$58.6M Sell
659,998
-29,630
-4% -$3.01M 2.62% 26
2014
Q4 		$61.1M Sell
689,628
-124,842
-15% -$11.8M 2.66% 26
2014
Q3 		$78.9M Sell
814,470
-318,082
-28% -$30.9M 3.47% 2
2014
Q2 		$104M Sell
1,132,552
-238,490
-17% -$18.2M 4.26% 1
2014
Q1 		$96M Buy
1,371,042
+66,852
+5% +$4.55M 3.81% 1
2013
Q4 		$75M Buy
1,304,190
+874,502
+204% +$46M 3.11% 14
2013
Q3 		$20.7M Buy
429,688
+418,706
+3,813% +$15.3M 0.95% 34
2013
Q2 		$318K Buy
+10,982
New +$318K 0.02% 65

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Daruma Capital Management's PCRX Position: Q2 2019 in Review

Daruma Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2019, closing a stake of 177,242 shares — an estimated $6.75M sold.

Daruma Capital Management first reported a position in PCRX in Q2 2013 and held it in 24 quarters. The position peaked at $104M in Q2 2014. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

  • Daruma Capital Management reported no remaining Pacira BioSciences position as of Q2 2019 after selling out during the quarter.
  • Daruma Capital Management sold 177,242 Pacira BioSciences shares in Q2 2019, an estimated $6.75M.
  • Daruma Capital Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 24 quarters.
  • Daruma Capital Management's Pacira BioSciences position peaked at $104M in Q2 2014.
  • 218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Daruma Capital Management's 13F filing for Q2 2019.